Advertisement

Picture EBD Group BIO-Europe 2021 Time to Register 650x100

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 6673 | Ordered by Date (descending)
1 2 3 ... 65 66 67  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners 2021-10-14
Rectify Pharmaceuticals–Forbion: investment, 202110 financing round Series A totalling $100m incl co-lead investor Forbion 2021-10-14
Rectify Pharmaceuticals–SEVERAL: investment, 202110 financing round Series A $100m co-led by Atlas Venture + Omega Funds + Forbion + Longwood Fund 2021-10-14
VeroVaccines–SEVERAL: investment, 202110 financing round Series B mid-7-figure € from consortium of investors from Germany + Switzerland 2021-10-14
SparingVision–Intellia Therapeutics: CRISPR technology, 202110– collab incl license to use CRISPR/Cas9 to develop genomic ocular disease treatments 2021-10-13
SparingVision–Intellia Therapeutics: investment, 202110 Intellia receives 10% equity ownership in SparingVision as part of collab/license agreem 2021-10-13
ISD Immunotech–Eir Ventures: investment, 202110 investment by new investor Eir Ventures 2021-10-11
ISD Immunotech–Novo Group: investment, 202110 existent lead investor Novo Seeds 2021-10-11
Autolomous–Image Box: public relations, 202110 service existent by Image Box Communications 2021-10-08
Bico–SEVERAL: investment, 202110 direct share issue SEK2.04b ($232m) with 4.25m Series B Shares at SEK480/share (= 5.6% discount) 2021-10-07
Creapaper–eCapital: investment, 202110 financing round Series B totalling €20m incl existing investor eCapital 2021-10-06
Creapaper–EU (govt): investment, 202110 financing round Series B totalling €20m incl new investor EIC Fund 2021-10-06
Creapaper–JS Capital: investment, 202110 financing round Series B totalling €20m incl new investor JS Capital 2021-10-06
Creapaper–Ranpak: investment, 202110 financing round Series B totalling €20m incl new investor Ranpak 2021-10-06
Creapaper–Schusterman Family Investments: investment, 202110 financing round Series B totalling €20m incl new investor Schusterman Family Investments 2021-10-06
Creapaper–SEVERAL: investment, 202110 financing round Series B €20m 2021-10-06
Creapaper–Soros Capital: investment, 202110 financing round Series B totalling €20m incl new investor Soros Capital 2021-10-06
Atbtherapeutics–Trophic Communications: public relations, 202110 service existent by Trophic Communications 2021-10-05
Cellecta–Merck (DE): CRISPR technology, 202110– license for CRISPR-Cas9 technology to Cellecta 2021-10-05
Exo Therapeutics–SEVERAL: investment, 202120 financing round Series B $78m lead by new investor Nextech invest 2021-10-05
iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG 2021-10-05
Synklino–Denmark (govt): investment, 202110– financing round targeting DKK35m incl existing + co-lead investor Vaekstfonden Venture 2021-10-05
Synklino–Eir Ventures: investment, 202110– financing round targeting DKK35m incl existing + co-lead investor Eir Ventures 2021-10-05
Synklino–SEVERAL: investment, 202110– financing round targeting DKK35m co-led by Eir Ventures + Vaekstfonden Venture 2021-10-05
Pierre Fabre–Atara Biotherapeutics: tabelecleucel, 202110– collab $45m upfront + $320m milestones + royalties excl sales in EMEA for EBV+ cancers 2021-10-04
Genetic Analysis (NO)–SEVERAL: investment, 202110 IPO at Swedish Spotlight Stock Market raising $6.8m 2021-10-03
QInstruments–Bico: investment, 202110– acquisition 100% cash/debt free for €58.25m upfront + €3m milestones thereof 13% paid in new Bico shares 2021-10-01
Aglaia Therapeutics–Advent France Biotechnology: investment, 202109 seed financing round totalling €4m incl co-founder + lead investor AFB 2021-09-27
Aglaia Therapeutics–Crédit Mutuel-CIC: investment, 202109 seed financing round totalling €4m incl co-investor Crédit Mutuel Innovation 2021-09-27
Aglaia Therapeutics–Pierre Fabre: investment, 202109 seed financing round totalling €4m incl co-investor Pierre Fabre 2021-09-27
Aglaia Therapeutics–SEVERAL: investment, 202109 seed financing round €4m led by Advent FB with Crédit Mutuel Innovation + Pierre Fabre 2021-09-27
Panakès Partners–Huntsworth: public relations, 202109 service existent by Medistrava Consulting 2021-09-27
AstraZeneca–VaxEquity: saRNA technology, 202109– collab up to $195m + royalties for up to 26 drug targets 2021-09-23
Thermo Fisher–Carbon Engineering: analytical technology, 202109 collab existent direct air capture technology to reduce CO2 emissions 2021-09-23
VaxEquity–AstraZeneca: investment, 202109 equity investment by AstraZeneca in connection with strategic research collab 2021-09-23
VaxEquity–Morningside: investment, 202109 equity investment by Morningside Ventures 2021-09-23
VaxEquity–Scius Communications: public relations, 202109 supply service existent by Scius Communications 2021-09-23
Univ Aarhus–Novo Group: grant, 202109–202808 grant DKK630m (€84.7m) to establish NNF CO2 Research Center at AU + six satellite institutes 2021-09-22
Accession Therapeutics–Birk Venture: investment, 202109 1st tranche of long-term funding round incl Birk Venture 2021-09-20
Accession Therapeutics–Primavera Capital: investment, 202109 1st tranche of long-term funding round incl Primavera Venture Partners 2021-09-20
Accession Therapeutics–SEVERAL: investment, 202109 1st tranche of long-term funding round incl Primavera Venture Partners + Birk Venture 2021-09-20
Intrance–PERSON: investment, 202109 investment $8m by Erik Selin Fastigheter AB as anchor investor of $15m Series A round of Intrance Medical Systems 2021-09-20
Jeito Capital–SEVERAL: investment, 202109 final closing Jeito I with addit €284m at €534m after €200m 1st close + €50m from Sanofi 2021-09-20
Biotest–Grifols: investment, 202109– public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share 2021-09-17
Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash 2021-09-17
Anjarium Biosciences–Abingworth: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Abingworth 2021-09-16
Anjarium Biosciences–Citadel: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Surveyor Capital 2021-09-16
Anjarium Biosciences–Gimv: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Gimv 2021-09-16
Anjarium Biosciences–Huntsworth: public relations, 202109 service existent by Medistrava Consulting 2021-09-16
Anjarium Biosciences–Omega Funds: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Omega Funds 2021-09-16
Anjarium Biosciences–Pfizer: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Pfizer Ventures 2021-09-16
Anjarium Biosciences–SEVERAL: investment, 202109 financing round Series A CHF55.5m ($61m) co-led by Abingworth + Gimv 2021-09-16
BRAIN Biotech–SEVERAL: investment, 202109 capital increase €19.6m with 1.99m new shares at €9.85/share to institutional investors 2021-09-15
Clean Biologics–Andrew Lloyd Associates: public relations, 202109 service existent for Clean Cells by ALA 2021-09-15
Clean Biologics–ArchiMed: investment, 202109 investment existent by ArchiMed 2021-09-15
Hurel–Bico: investment, 202109 acquisition $2.5m of assets + operations of Hurel Corp + integration in Visikol 2021-09-15
Touchlight–Bridford Group: investment, 202109 financing round extension £50m incl co-lead investor Bridford Investments Ltd 2021-09-15
Touchlight–Novator Partners: investment, 202109 financing round extension £50m incl co-lead investor Novator Partners 2021-09-15
Touchlight–SEVERAL: investment, 202109 financing round extension £50m bringing total round to £92m led by Bridford + Novator 2021-09-15
Evotec–Biognosys: MS-based proteomics, 202109– collab integration of Spectronaut proteomics data analys into drug discovery + clinical proteomics 2021-09-14
Meatable–DSM: cell culture media, 202109– collab developm growth media for cultivated meat 2021-09-13
TreeFrog Therapeutics–BMS: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor BMS 2021-09-13
TreeFrog Therapeutics–France (govt): investment, 202109 financing round Series B totalling $75m (€64m) incl lead investor Bpifrance Large Venture 2021-09-13
TreeFrog Therapeutics–Leonard Green: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor Leonard Green + Partners LP 2021-09-13
TreeFrog Therapeutics–SEVERAL: investment, 202109 financing round Series B $75m (€64m) led by Bpifrance Large Venture 2021-09-13
TreeFrog Therapeutics–Siparex: investment, 202109 financing round Series B totalling $75m (€64m) incl exisiting + co-investor XAnge 2021-09-13
Genedrive–SEVERAL: investment, 202109– capital increase open offer up to £4.5m with up to 18.1m shares at 25p/share w 40.1% discount ANNOUNCED 2021-09-10
Genedrive–SEVERAL: investment, 202109–202110 capital increase placing £6m (net £5.6m) with 24m new ordinary shares at 25p/share w 40.1% discount 2021-09-10
Genedrive–Walbrook PR: public relations, 202109 service existent by Walbrook PR 2021-09-10
Boehringer–Twist Bioscience: antibody drug discovery, 202109– collab using Twist Biopharma antibody phage display libraries against Boehringer targets 2021-09-09
TIB Molbiol–Roche: investment, 202109– acquisition 100% of TIB Mobiol Group by Roche SIGNED 2021-09-09
EnteroBiotix–Kineticos Life Sciences: investment, 202109 financing round Series A totalling £15.5m incl new + co-investor KIneticos Ventures 2021-09-07
EnteroBiotix–Scius Communications: public relations, 202109 supply service existent by Scius Communications 2021-09-07
EnteroBiotix–Scotland (govt): investment, 202109 financing round Series A totalling £15.5m incl existing + co-investor Scottish Enterprise 2021-09-07
EnteroBiotix–SEVERAL: investment, 202109 financing round Series A £15.5m ($21.5m) led by Thairm Bio 2021-09-07
EnteroBiotix–Social Investment Scotland: investment, 202109 financing round Series A totalling £15.5m incl existing + co-investor SIS Ventures 2021-09-07
EnteroBiotix–Thairm Bio: investment, 202109 financing round Series A totalling £15.5m incl lead investor Thairm Bio 2021-09-07
Owlstone–Horizons Ventures: investment, 202109 financing round Series D totalling $58m incl existing + lead investor Horizons Ventures 2021-09-07
Owlstone–SEVERAL: investment, 202109 financing round Series D $58m of Owlstone Medical led by existing investor Horizons Ventures 2021-09-07
ImmunOs Therapeutics–Akampion: public relations, 202109 service existent by Akampion 2021-09-01
Ascendis Pharma–SEVERAL: investment, 202108– public offering $400m + up to $60m of ADSs 2021-08-31
Tissium–Cathay Capital: investment, 202108 financing round Series C totalling €50m incl new + co-lead investor Cathay Health 2021-08-31
Tissium–SEVERAL: investment, 202108 financing round Series C €50m co-led by Cathay Health + Sofinnova Partners 2021-08-31
Tissium–Sofinnova: investment, 202108 financing round Series C totalling €50m incl existing + co-lead investor Sofinnova Partners 2021-08-31
NürnbergMesse–Messe Stuttgart: T4M trade show, 202108 acquistion of T4M event from Messe Stuttgart by MedtecLIVE GmbH 2021-08-30
Biognosys–ETH Zürich: LiP technology, 202108 collab developm + excl license from Institute of Systems Biology 2021-08-27
HealthCare Royalty–ADC Therapeutics: antibody-drug conjugates, 202108 acquisition $225m upfront + $100m milestones royalty rights to Zynlonta + Cami 2021-08-26
Afyren–SEVERAL: investment, 202108– IPO at Euronext Growth Paris registration document filed 2021-08-25
Cardior Pharmaceuticals–ABP (NL): investment, 202108 financing round Series B totalling €64m incl new + lead investor Inkef Capital 2021-08-25
Cardior Pharmaceuticals–BioMedPartners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BioMedPartners 2021-08-25
Cardior Pharmaceuticals–BMS: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BMS 2021-08-25
Cardior Pharmaceuticals–Fund+: investment, 202108 financing round Series B totalling €64m incl new + co-investor Fund+ 2021-08-25
Cardior Pharmaceuticals–Germany (govt): investment, 202108 financing round Series B totalling €64m incl new + co-investor Coparion 2021-08-25
Cardior Pharmaceuticals–Hadean Ventures: investment, 202108 financing round Series B totalling €64m incl new + co-investor Hadean Ventures 2021-08-25
Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 202108 financing round Series B totalling €64m incl existing + co-investor HTGF 2021-08-25
Cardior Pharmaceuticals–Life Sciences Partners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor LSP 2021-08-25
Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital 2021-08-25
Cardior Pharmaceuticals–Sunstone Life Science: investment, 202108 financing round Series B totalling €64m incl new + co-investor Sunstone 2021-08-25
Cardior Pharmaceuticals–Trophic Communications: public relations, 202108 service existent by Trophic Communications 2021-08-25
FarmInsect–5x Ventures: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor 5x Ventures 2021-08-17
1 2 3 ... 65 66 67  next pagenext page



Advertisement

Picture [iito] Made Without Love 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture [iito] Back into Ad 650x80px

» top